

AF 1644-1
1FEW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 2, 2007

Signature: _____

(Merlin Aubourg)

Docket No.: WYS-004.01
(PATENT)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Man Sung Co *et al.*

Application No.: 09/501,102

Filed: February 9, 2000

For: HUMANIZED IMMUNOGLOBULIN
REACTIVE WITH B7 MOLECULES AND
METHODS OF TREATMENT HERewith



Confirmation No.: 3404

Art Unit: 1644

Examiner: P. Gambel

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER CFR 1.97(c)(2)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97(c)(2) and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

02/05/2007 TBESHAX1 00000338 061448 09501102
01 FC:1806 180.00 DA

Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please charge our Deposit Account No. 06-1448 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Deposit Account No. 06-1448, under Reference No. WYS-004.01**. A duplicate copy of this paper is enclosed.

Dated: February 2, 2007

Respectfully submitted,

By 

Charlene A. Stern-Dombal, Ph.D.

Registration No.: 57,961

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1738

Agent for Applicant



PTO/SB/08A/B (09-08)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/501,102-Conf. #3404		
		Filing Date	February 9, 2000		
		First Named Inventor	Man Sung Co		
		Art Unit	1644		
		Examiner Name	P. Gambel		
Sheet	1	of	3	Attorney Docket Number	WYS-004.01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,397,703	03-14-1995	De Boer et al.	
	AB*	US-5,562,903	10-08-1996	Co et al.	
	AC*	US-5,622,701	04-22-1997	Berg	
	AD*	US-5,869,050	02-09-1999	de Boer et al.	
	AE*	US-5,919,449	07-06-1999	Dinsmore	
	AF*	US-5,977,318	11-02-1999	Linsley et al.	
	AG*	US-6,084,067	07-04-2000	Freeman et al.	
	AH*	US-6,096,537	08-01-2000	Chappel	
	AI*	US-6,130,316	10-10-2000	Freeman et al.	
	AJ*	US-6,346,248	02-12-2002	De Boer et al.	
	AK*	US-6,608,180	08-19-2003	Sharpe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 94/01547	01-20-1994			
	BB	WO 95/34320	12/1995			
	BC	WO 98/19706	05-14-1998			
	BD	WO 00/19706	04-06-2000			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Azuma et al., "B70 antigen is a second ligand for CTLA-2 and CD28," Nature, 366:76-79 (1993)	
	CB	Berzofsky et al., "Antigen-Antibody Interaction," In Fundamental Immunology, W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984)	
	CC	Bluestone, J.A., "Costimulation and its role in organ transplantation," Clinical Transplantation, 10:104-109 (1996)	
	CD	Chen et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992)	
	CE	Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," The J. of Immunology, 148(4):1149-1154 (1992)	
	CF	Cromwell et al., Abstract: "The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation," Experimental Biology 98 Meeting, April 22, 1998	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/501,102-Conf. #3404
				Filing Date	February 9, 2000
				First Named Inventor	Man Sung Co
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	2	of	3	Attorney Docket Number	WYS-004.01

CG	Daikh et al., "The CD28-B7 costimulatory pathway and its role in autoimmune disease," J. of Leukocyte Biol., 62:156-162 (1997)	
CH	Damico et al., "Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomolgus Monkeys," Abstract, 17th Annual Scientific Meeting, January 9, 1998	
CI	Engel et al., "The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes is the CD86 Differentiation antigen," Blood, 84(5):1402-1407 (1994)	
CJ	Fleischer et al., "Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes," Immunology, 89:592-598 (1996)	
CK	Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogeneicity," Blood 87(6):2386-2393 (1996)	
CL	Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992)	
CM	Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perfusion technique," Transplant Immunology, 2:27-34 (1994)	
CN	Harlow and Lane (Eds) Antibodies: A Laboratory Manual, Coldspring Harbor Laboratory 1988, pp. 23-35.	
CO	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993)	
CP	Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)	
CQ	Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, Edgbaston, Birmingham, pp. 115-126	
CR	Levitt, M., "Molecular Dynamics of Native Protein," J. Mol. Biol., 168:595-620 (1983)	
CS	Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810	
CT	Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)	
CU	Morrison et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)	
CV	NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, G1121042 (July 21, 1986)	
CW	Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)	
CX	Reiser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)	
CY	Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)	
CZ	Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)	
CA1	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)	
CB1	Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-Transfected Melanoma Cells," Science, 259:368-369 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/501,102-Conf. #3404
				Filing Date	February 9, 2000
				First Named Inventor	Man Sung Co
				Art Unit	1644
				Examiner Name	P. Gambel
				Attorney Docket Number	WYS-004.01
Sheet	3	of	3		

CC1	Yokozeki et al., "Functional CD86 (B7-B70) on Cultured Human Langerhans Cells," The Society for Investigative Dermatology, Inc., 106:147-153 (1996)	
-----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--